BridgeBio Oncology Therapeutics Inc. (BBOT)
NASDAQ: BBOTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BBOT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $145.25M
- P/E (TTM)
- 3.42
- EPS (TTM)
- $0.53
- Dividend yield
- None
- 52-week range
- 1.79 – 14.87
- Day range
- 1.79 – 1.94
- Volume / Avg
- 450.96K / 631.56K
- Beta
- —
- Shares outstanding
- 80.25M
52-week range
BBOT stock today
On Nov 20, BBOT ended the session at $1.81, shedding $0.05 (2.69%), versus the S&P 500's 3.70% decline. Shares are 87.8% below their 52-week high of $14.87, set on Dec 8, 2025 and 1.4% above the 52-week low of $1.79, near the bottom of the past year's range. BBOT is down 85.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.4%.
BridgeBio Oncology Therapeutics trades at 3.4x its trailing twelve-month earnings per share of $0.53.
Summary generated from market data by MetaCap's automated system. Methodology
About BridgeBio Oncology Therapeutics
Company profileBridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Pedro J. Beltran M.D., Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 92
- IPO year
- 2024
- Website
- bbotx.com
Financial highlights
Full financialsBridgeBio Oncology Therapeutics reported a net loss of $134.0 million, compared with a loss of $74.3 million a year earlier. Diluted earnings per share came in at -$4.30.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-134.04M | $-74.28M | $-41.69K |
| EPS (diluted) | $-4.30 | $-5,756.41 | — |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$21.00+1060.22%
- Strong buy 4
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.43 vs $-0.65
- Surprise
- +33.85%
BBOT news
All BBOT newsBridgeBio Oncology Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRQRProQR Therapeutics N.V. | 1.04 | -0.95% | $146.98M | vs BBOT |
| VRXAVeraxa Biotech AG | 1.04 | +0.97% | $147.06M | vs BBOT |
| RNAAtrium Therapeutics Inc. | 6.92 | -0.86% | $149.27M | vs BBOT |
| ELDNEledon Pharmaceuticals Inc. | 1.78 | -6.32% | $150.34M | vs BBOT |
| IFRXInflaRx N.V. | 1.04 | -4.59% | $153.26M | vs BBOT |
| ALXOALX Oncology Holdings Inc. | 1.06 | +3.92% | $137.03M | vs BBOT |
| ORMPOramed Pharmaceuticals Inc. | 3.57 | -3.25% | $155.24M | vs BBOT |
| ZNTLZentalis Pharmaceuticals Inc. | 1.36 | 0.00% | $133.64M | vs BBOT |
Indexes, lists and sector
BridgeBio Oncology Therapeutics stock FAQ
What is BridgeBio Oncology Therapeutics's stock price today?
BBOT last traded at $1.81 as of Nov 20, 4:00 PM EST, down 2.69% on the day. Prices are delayed at least 15 minutes.
What is BBOT's P/E ratio?
BBOT trades at a trailing P/E ratio of 3.42.
Who is BridgeBio Oncology Therapeutics's CEO?
Dr. Pedro J. Beltran M.D., Ph.D. is the chief executive officer of BridgeBio Oncology Therapeutics Inc., which has about 92 employees.
What is the BBOT 52-week high?
The 52-week high for BBOT is $14.87 and the 52-week low is $1.79. The stock is currently 87.8% below its high.